Phase I/II Study of Alectinib (CH5424802/RO5424802) in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC): Updated Results from the AF-001JP Trial | Zendy

AI Assistant Blog Pricing

Phase I/II Study of Alectinib (CH5424802/RO5424802) in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC): Updated Results from the AF-001JP Trial

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.